Meningococcal B vax rejection a bad move: expert

A LEADING immunisation researcher says rejection of funding for the meningococcal B vaccine suggests the government’s advisory committee isn’t accurately estimating the cost of the disease to the community.

Paediatric infectious diseases specialist Professor Robert Booy has criticised the Pharmaceutical Benefits Advisory Committee (PBAC) for rejecting listing of MenBV, also known as 4CMenB (Bexsero, GSK), pointing out that the UK is adding the vaccine to its childhood schedule.

“Whatever reservations the PBAC has, they are not shared